Market Place
Sourcing Support
Nuvalent to Join Stifel 2025 Virtual Oncology Forum
01 Apr 2025 //
PR NEWSWIRE
Nuvalent To Present Data On Neladalkib, Zidesamtin At AACR 2025
25 Mar 2025 //
PR NEWSWIRE
Nuvalent Targets 2026 Approval With Key 2025 Milestones Outlined
13 Jan 2025 //
PR NEWSWIRE
Nuvalent to Present at 43rd J.P. Morgan Healthcare Conference
19 Dec 2024 //
PR NEWSWIRE
Nuvalent Appoints Grant Bogle to Board of Directors
09 Dec 2024 //
PR NEWSWIRE
Nuvalent Highlights Pipeline Achievements & Reports Q3 2024 Results
12 Nov 2024 //
PR NEWSWIRE
Nuvalent Announces Public Offering of Common Stock
16 Sep 2024 //
PR NEWSWIRE
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
16 Sep 2024 //
PR NEWSWIRE
Nuvalent Announces Publication On ALK-Selective Inhibitor NVL-655
13 Sep 2024 //
PR NEWSWIRE
Nuvalent Shares Updated Data On ALK And ROS1 Inhibitors
09 Sep 2024 //
PR NEWSWIRE
Nuvalent To Participate In Morgan Stanley Healthcare Conference
29 Aug 2024 //
PR NEWSWIRE
Nuvalent Reports Q2 2024 Results And Highlights Pipeline Progress
08 Aug 2024 //
PR NEWSWIRE
Nuvalent Doses First Patient In HEROEX-1 Trial Of NVL-330
22 Jul 2024 //
PR NEWSWIRE
Nuvalent To Present ROS1 And ALK Inhibitor Data At ESMO 2024
16 Jul 2024 //
PR NEWSWIRE
Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer
11 Jul 2024 //
PR NEWSWIRE
Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference
30 May 2024 //
PR NEWSWIRE
US FDA grants breakthrough therapy designation to Nuvalent’s NVL-655 t
18 May 2024 //
PHARMABIZ
Nuvalent Pipeline Progress, Milestones, Q1 2024 Financials
09 May 2024 //
PR NEWSWIRE
Nuvalent Presents New Preclinical Data of Zidesamtinib at AACR
08 Apr 2024 //
PR NEWSWIRE
Nuvalent to Present New Preclinical Data on NVL-330, and zidesamtinib
05 Mar 2024 //
PR NEWSWIRE
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
27 Feb 2024 //
PR NEWSWIRE
Nuvalent Highlights Pipeline Progress
27 Feb 2024 //
PR NEWSWIRE
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for NSCLC
12 Feb 2024 //
PR NEWSWIRE
Nuvalent to Participate in the 6th Annual Biotechnology Conference
01 Feb 2024 //
PR NEWSWIRE
Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones
08 Jan 2024 //
PR NEWSWIRE
Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference
21 Dec 2023 //
PR NEWSWIRE
Nuvalent Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
PR NEWSWIRE
Nuvalent to Participate in the BMO BioPharma Spotlight Series: Oncology Day
01 Nov 2023 //
PR NEWSWIRE
Why Nuvalent Stock Tanked on Tuesday
17 Oct 2023 //
FOOL
Nuvalent Announces Pricing of Public Offering of Common Stock
16 Oct 2023 //
PR NEWSWIRE
Nuvalent Announces Public Offering of Common Stock
16 Oct 2023 //
PR NEWSWIRE
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial
13 Oct 2023 //
PR NEWSWIRE
Why Nuvalent Stock Skyrocketed 35% This Week
05 Oct 2023 //
FOOL
Phase 1 Data Trial of NVL-655 Demonstrated Activity in Pre-Treated Patients
04 Oct 2023 //
PRESS RELEASE
Stifel Initiates Coverage on Nuvalent Inc with Positive Outlook
27 Sep 2023 //
BEST STOCKS
Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth
23 Sep 2023 //
SIMPLYWALL
Nuvalent to Present Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655
18 Sep 2023 //
PRESS RELEASE
Nuvalent Initiates the Phase 2 Portion of ARROS-1 Trial for Patients with NSCLC
05 Sep 2023 //
PR NEWSWIRE
Nuvalent Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
PR NEWSWIRE
Nuvalent to Participate in Upcoming August Investor Conferences
01 Aug 2023 //
PR NEWSWIRE
Nuvalent Announces Anticipated Timing of Preliminary Ph 1 Dose Data for NVL-655
11 May 2023 //
PR NEWSWIRE
Nuvalent Presents New Preclinical Data of NVL-655 at AACR Annual Meeting 2023
18 Apr 2023 //
PR NEWSWIRE
Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655
23 Mar 2023 //
PR NEWSWIRE
Nuvalent Reports Fourth Quarter and Full Year 2022 Financial Results
16 Mar 2023 //
PR NEWSWIRE
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655
14 Mar 2023 //
PRESS RELEASE
Nuvalent to Participate in the 43rd Annual Cowen Healthcare Conference
01 Mar 2023 //
PR NEWSWIRE
Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
PR NEWSWIRE
Nuvalent to Publish Detailing Design of ROS1-selective inhibitor NVL-520
13 Dec 2022 //
PRNEWSWIRE
Nuvalent Reviews Corporate and Pipeline Achievements and Reports 3Q 2022 FYR
10 Nov 2022 //
PRNEWSWIRE
Nuvalent Announces Closing of Upsized Public Offering of Common Stock
03 Nov 2022 //
PRESS RELEASE
Nuvalent Announces Pricing of Public Offering of Common Stock
31 Oct 2022 //
PRNEWSWIRE
Nuvalent nets $200M public offering in wake of positive PhI data, future trials
31 Oct 2022 //
ENDPTS
Nuvalent Reports Preliminary PI Data from ARROS-1 Trial that Support NVL-520
28 Oct 2022 //
PRESS RELEASE
Taking on Big Pharma rivals, biotech startup unveils first-in-human data ROS1
28 Oct 2022 //
ENDPTS
Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial
27 Oct 2022 //
PRNEWSWIRE
Nuvalent to Host Conference to Discuss PhI Data from ARROS-1 Trial of NVL-520
17 Oct 2022 //
PRNEWSWIRE
Nuvalent Appoints Michael Meyers to Board of Directors
06 Oct 2022 //
PRNEWSWIRE
Nuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors
06 Oct 2022 //
PRNEWSWIRE
Nuvalent to Present Phase 1 Data from ARROS-1 Clinical Trial of NVL-520
07 Sep 2022 //
PRNEWSWIRE
Nuvalent to Participate in the Wells Fargo 2022 Healthcare Conference
01 Sep 2022 //
PRNEWSWIRE
